David Bruce Light

Title: Innovations by David Bruce Light

Introduction

David Bruce Light is an accomplished inventor based in San Mateo, CA. He has made significant contributions to the field of medical science, particularly in the development of novel anticoagulant therapies. With a total of 2 patents, his work focuses on innovative solutions for thrombotic conditions.

Latest Patents

David's latest patents include groundbreaking inventions that utilize novel tissue factor targeted thrombomodulin fusion proteins as anticoagulants. This invention relates to fusion proteins that consist of a targeting protein binding to tissue factor (TF), operably linked to the thrombomodulin (TM) EGF456 domain. These proteins can be combined with other TM domains, such as the N-terminal hydrophobic region domain, the EGF123 domain, and others. The fusion protein effectively binds at the site of injury, preventing the initiation of thrombosis. It has potential applications in treating various thrombotic conditions, including deep vein thrombosis, disseminated intravascular coagulation, and acute coronary syndrome. Another patent focuses on polynucleotides encoding these anticoagulant fusion proteins, further emphasizing the innovative nature of his work.

Career Highlights

David Bruce Light is currently associated with Bayer Schering Pharma AG, where he continues to advance his research and development efforts. His work has garnered attention for its potential to improve patient outcomes in thrombotic conditions.

Collaborations

David collaborates with Kirk McLean, leveraging their combined expertise to drive innovation in their field.

Conclusion

David Bruce Light's contributions to medical science through his patents and collaborations highlight his commitment to advancing healthcare solutions. His innovative work in anticoagulant therapies has the potential to make a significant impact on the treatment of thrombotic conditions.